Issue
Date Log
Copyright (c) 2026 Matar Omishan Alhazmi, Rizgallah Farj Alrawili, Musleh Sayer Alshammari, Sami Jumah K. Alhazmi, Lazzam Mubarak Al-Anazi, Gadan Saif Alotaibi, Muteb Ghazai Alotaibi, Hanan Sneed Alharbi, Maryam Sulaiman Alhejaili, Baqer Hussain Alhadab

This work is licensed under a Creative Commons Attribution 4.0 International License.
Hydroxyurea Toxicity: Emergency Recognition, Clinical Management, and Nursing and Respiratory Care Considerations
Corresponding Author(s) : Matar Omishan Alhazmi
Saudi Journal of Medicine and Public Health,
Vol. 3 No. 1 (2026)
Abstract
Background: Hydroxyurea is an antimetabolite medication used in the management of several hematological and oncological disorders, as well as sickle cell disease. Although generally well tolerated when prescribed and monitored appropriately, excessive exposure, dosing errors, impaired renal clearance, and prolonged treatment may result in clinically significant toxicity. Its major adverse effects include bone marrow suppression, gastrointestinal complications, mucocutaneous lesions, and, less frequently, neurological and pulmonary manifestations. Severe toxicity may lead to infection, bleeding, respiratory compromise, and other life-threatening complications.
Aim: This review aims to examine the clinical features, underlying mechanisms, diagnostic evaluation, and management of hydroxyurea toxicity, with particular attention to emergency recognition and the contributions of nursing and respiratory care professionals.
Methods: A narrative review approach was used to organize available clinical and pharmacological evidence concerning hydroxyurea toxicity. The review addresses its etiology, epidemiology, pathophysiology, toxicokinetics, clinical manifestations, diagnostic investigations, treatment strategies, differential diagnosis, and interprofessional management.
Results: Hydroxyurea toxicity primarily results from inhibition of ribonucleotide reductase, leading to impaired DNA synthesis and suppression of rapidly dividing cells, particularly bone marrow precursors. Clinical manifestations include anemia, neutropenia, thrombocytopenia, gastrointestinal disturbances, oral mucositis, skin ulceration, and neurological abnormalities. Evaluation requires medication and exposure history, complete blood counts, renal function assessment, and symptom-directed investigations. Management is mainly supportive and may include fluid replacement, blood product transfusion, growth factor administration, infection management, and treatment of specific complications.
Conclusion: Early recognition, appropriate monitoring, supportive treatment, and coordinated interprofessional care are essential to reducing complications and improving outcomes in patients with hydroxyurea toxicity.
Keywords
Download Citation
Endnote/Zotero/Mendeley (RIS)BibTeX
- 1. Finazzi G, Barbui T. How I treat patients with polycythemia vera. Blood. 2007 Jun 15;109(12):5104-11.
- 2. Barbui T, Barosi G, Grossi A, Gugliotta L, Liberato LN, Marchetti M, Mazzucconi MG, Rodeghiero F, Tura S. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica. 2004 Feb;89(2):215-32.
- 3. Miller ST, Rey K, He J, Flanagan J, Fish BJ, Rogers ZR, Wang WC, Ware RE., BABY HUG Investigators. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatr Blood Cancer. 2012 Jul 15;59(1):170-2.
- 4. Brincker H, Christensen BE. Acute mucocutaneous toxicity following high-dose hydroxyurea. Cancer Chemother Pharmacol. 1993;32(6):496-7.
- 5. Yarbro JW. Mechanism of action of hydroxyurea. Semin Oncol. 1992 Jun;19(3 Suppl 9):1-10.
- 6. Krakoff IH, Brown NC, Reichard P. Inhibition of ribonucleoside diphosphate reductase by hydroxyurea. Cancer Res. 1968 Aug;28(8):1559-65.
- 7. Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet. 2010 Dec 11;376(9757):2018-31.
- 8. Eridani S, Mosca A. Fetal hemoglobin reactivation and cell engineering in the treatment of sickle cell anemia. J Blood Med. 2011;2:23-30.
- 9. Hankins J, Aygun B. Pharmacotherapy in sickle cell disease--state of the art and future prospects. Br J Haematol. 2009 May;145(3):296-308.
- 10. Ware RE, Despotovic JM, Mortier NA, Flanagan JM, He J, Smeltzer MP, Kimble AC, Aygun B, Wu S, Howard T, Sparreboom A. Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia. Blood. 2011 Nov 03;118(18):4985-91.
- 11. Gwilt PR, Tracewell WG. Pharmacokinetics and pharmacodynamics of hydroxyurea. Clin Pharmacokinet. 1998 May;34(5):347-58.
- 12. Randi ML, Ruzzon E, Luzzatto G, Tezza F, Girolami A, Fabris F. Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders. Haematologica. 2005 Feb;90(2):261-2.
- 13. Liozon E, Brigaudeau C, Trimoreau F, Desangles F, Fermeaux V, Praloran V, Bordessoule D. Is treatment with hydroxyurea leukemogenic in patients with essential thrombocythemia? An analysis of three new cases of leukaemic transformation and review of the literature. Hematol Cell Ther. 1997 Feb;39(1):11-8.
- 14. Estève E, Georgescu V, Heitzmann P, Martin L. [Multiple skin and mouth squamous cell carcinomas related to long-term treatment with hydroxyurea]. Ann Dermatol Venereol. 2001 Sep;128(8-9):919-21.
- 15. Antonioli E, Guglielmelli P, Pieri L, Finazzi M, Rumi E, Martinelli V, Vianelli N, Luigia Randi M, Bertozzi I, De Stefano V, Za T, Rossi E, Ruggeri M, Elli E, Cacciola R, Cacciola E, Pogliani E, Rodeghiero F, Baccarani M, Passamonti F, Finazzi G, Rambaldi A, Bosi A, Cazzola M, Barbui T, Vannucchi AM., AGIMM Investigators. Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN. Am J Hematol. 2012 May;87(5):552-4.
- 16. Hernández-Boluda JC, Alvarez-Larrán A, Gómez M, Angona A, Amat P, Bellosillo B, Martínez-Avilés L, Navarro B, Teruel A, Martínez-Ruiz F, Besses C. Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia. Br J Haematol. 2011 Jan;152(1):81-8.
- 17. Latagliata R, Spadea A, Cedrone M, Di Giandomenico J, De Muro M, Villivà N, Breccia M, Anaclerico B, Porrini R, Spirito F, Rago A, Avvisati G, Alimena G, Montanaro M, Andriani A., Gruppo Laziale SMPC Ph1 neg. Symptomatic mucocutaneous toxicity of hydroxyurea in Philadelphia chromosome-negative myeloproliferative neoplasms: the Mister Hyde face of a safe drug. Cancer. 2012 Jan 15;118(2):404-9.
- 18. Leo E, Krämer A, Hochhaus A, Krasniqi F, Hehlmann R, Ho AD. Gangrene of the toes in a patient with chronic myelogenous leukemia after long-term hydroxyurea therapy. Ann Hematol. 2002 Aug;81(8):467-9.
- 19. Salmon-Ehr V, Leborgne G, Vilque JP, Potron G, Bernard P. [Secondary cutaneous effects of hydroxyurea: prospective study of 26 patients from a dermatologic consultation]. Rev Med Interne. 2000 Jan;21(1):30-4.
- 20. Berthaut I, Guignedoux G, Kirsch-Noir F, de Larouziere V, Ravel C, Bachir D, Galactéros F, Ancel PY, Kunstmann JM, Levy L, Jouannet P, Girot R, Mandelbaum J. Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males. Haematologica. 2008 Jul;93(7):988-93.
- 21. Internullo M, Giannelli V, Sardo L, Antonaglia C, Villani T, Angelici E, Palange P. Hydroxyurea-induced interstitial pneumonitis: case report and review of the literature. Eur Rev Med Pharmacol Sci. 2014;18(2):190-3.
- 22. Kälsch H, Wieneke H, Erbel R. Acute myocardial infarction in a patient with chronic myelocytic leukemia during chemotherapy with hydroxyurea. Herz. 2010 Sep;35(6):420-2.
References
1. Finazzi G, Barbui T. How I treat patients with polycythemia vera. Blood. 2007 Jun 15;109(12):5104-11.
2. Barbui T, Barosi G, Grossi A, Gugliotta L, Liberato LN, Marchetti M, Mazzucconi MG, Rodeghiero F, Tura S. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica. 2004 Feb;89(2):215-32.
3. Miller ST, Rey K, He J, Flanagan J, Fish BJ, Rogers ZR, Wang WC, Ware RE., BABY HUG Investigators. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatr Blood Cancer. 2012 Jul 15;59(1):170-2.
4. Brincker H, Christensen BE. Acute mucocutaneous toxicity following high-dose hydroxyurea. Cancer Chemother Pharmacol. 1993;32(6):496-7.
5. Yarbro JW. Mechanism of action of hydroxyurea. Semin Oncol. 1992 Jun;19(3 Suppl 9):1-10.
6. Krakoff IH, Brown NC, Reichard P. Inhibition of ribonucleoside diphosphate reductase by hydroxyurea. Cancer Res. 1968 Aug;28(8):1559-65.
7. Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet. 2010 Dec 11;376(9757):2018-31.
8. Eridani S, Mosca A. Fetal hemoglobin reactivation and cell engineering in the treatment of sickle cell anemia. J Blood Med. 2011;2:23-30.
9. Hankins J, Aygun B. Pharmacotherapy in sickle cell disease--state of the art and future prospects. Br J Haematol. 2009 May;145(3):296-308.
10. Ware RE, Despotovic JM, Mortier NA, Flanagan JM, He J, Smeltzer MP, Kimble AC, Aygun B, Wu S, Howard T, Sparreboom A. Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia. Blood. 2011 Nov 03;118(18):4985-91.
11. Gwilt PR, Tracewell WG. Pharmacokinetics and pharmacodynamics of hydroxyurea. Clin Pharmacokinet. 1998 May;34(5):347-58.
12. Randi ML, Ruzzon E, Luzzatto G, Tezza F, Girolami A, Fabris F. Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders. Haematologica. 2005 Feb;90(2):261-2.
13. Liozon E, Brigaudeau C, Trimoreau F, Desangles F, Fermeaux V, Praloran V, Bordessoule D. Is treatment with hydroxyurea leukemogenic in patients with essential thrombocythemia? An analysis of three new cases of leukaemic transformation and review of the literature. Hematol Cell Ther. 1997 Feb;39(1):11-8.
14. Estève E, Georgescu V, Heitzmann P, Martin L. [Multiple skin and mouth squamous cell carcinomas related to long-term treatment with hydroxyurea]. Ann Dermatol Venereol. 2001 Sep;128(8-9):919-21.
15. Antonioli E, Guglielmelli P, Pieri L, Finazzi M, Rumi E, Martinelli V, Vianelli N, Luigia Randi M, Bertozzi I, De Stefano V, Za T, Rossi E, Ruggeri M, Elli E, Cacciola R, Cacciola E, Pogliani E, Rodeghiero F, Baccarani M, Passamonti F, Finazzi G, Rambaldi A, Bosi A, Cazzola M, Barbui T, Vannucchi AM., AGIMM Investigators. Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN. Am J Hematol. 2012 May;87(5):552-4.
16. Hernández-Boluda JC, Alvarez-Larrán A, Gómez M, Angona A, Amat P, Bellosillo B, Martínez-Avilés L, Navarro B, Teruel A, Martínez-Ruiz F, Besses C. Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia. Br J Haematol. 2011 Jan;152(1):81-8.
17. Latagliata R, Spadea A, Cedrone M, Di Giandomenico J, De Muro M, Villivà N, Breccia M, Anaclerico B, Porrini R, Spirito F, Rago A, Avvisati G, Alimena G, Montanaro M, Andriani A., Gruppo Laziale SMPC Ph1 neg. Symptomatic mucocutaneous toxicity of hydroxyurea in Philadelphia chromosome-negative myeloproliferative neoplasms: the Mister Hyde face of a safe drug. Cancer. 2012 Jan 15;118(2):404-9.
18. Leo E, Krämer A, Hochhaus A, Krasniqi F, Hehlmann R, Ho AD. Gangrene of the toes in a patient with chronic myelogenous leukemia after long-term hydroxyurea therapy. Ann Hematol. 2002 Aug;81(8):467-9.
19. Salmon-Ehr V, Leborgne G, Vilque JP, Potron G, Bernard P. [Secondary cutaneous effects of hydroxyurea: prospective study of 26 patients from a dermatologic consultation]. Rev Med Interne. 2000 Jan;21(1):30-4.
20. Berthaut I, Guignedoux G, Kirsch-Noir F, de Larouziere V, Ravel C, Bachir D, Galactéros F, Ancel PY, Kunstmann JM, Levy L, Jouannet P, Girot R, Mandelbaum J. Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males. Haematologica. 2008 Jul;93(7):988-93.
21. Internullo M, Giannelli V, Sardo L, Antonaglia C, Villani T, Angelici E, Palange P. Hydroxyurea-induced interstitial pneumonitis: case report and review of the literature. Eur Rev Med Pharmacol Sci. 2014;18(2):190-3.
22. Kälsch H, Wieneke H, Erbel R. Acute myocardial infarction in a patient with chronic myelocytic leukemia during chemotherapy with hydroxyurea. Herz. 2010 Sep;35(6):420-2.